• info@haemophiliawales.org


Some people with severe Haemophilia develop an antibody or inhibitor to factor treatment. When the factor is given for a bleed there is no clinical response because the activity is immediately neutralised. Often the first sign that a person has inhibitors is that his treatment does not appear to be working.

Roche’s Emicizumab is a subcutaneous (under the skin) once weekly injection and is currently being included in the UK early access to medicines scheme for patients with Haemophilia A and an Inhibitor.

February 2018 EU regulators grant licence for Emicizumab for people with Haemophilia A with Inhibitors to Factor 8.